New York, New York, USA, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Aletheia Capital Endeavours (ACE) today announced the launch of RepIntel, a precision field-intelligence platform designed to close one of ...

Prenetics Global Limited (“Prenetics” or the “Company”), a leading health sciences company, today announced that it has commenced a public offering of shares of its Class A Ordinary Shares (or ...

Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company's website at ...

Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (800) 715-9871 (U.S. callers) and (646) 307-1963 (International ...

Pennant invites current and prospective investors to tune into a live webcast to be held the following day, Thursday, November 6, 2025, at 10:00 a.m. Mountain Time (12:00 p.m. Eastern Time), during ...

The Amendment was recommended by a special committee of the independent directors of Enzon and was recommended by a special committee of the independent directors of Viskase and, acting upon such ...

To access the live webcast for BridgeBio's calls, please visit the “Events and Presentations” page within the Investors section of the BridgeBio website at https://investor.bridgebio.com. A replay of ...

In the ovarian cancer cohort, the median time to response was 1.3 months and median duration of response was 8.0 months. Post the September 4, 2025 data cutoff date, four uPRs were confirmed and one ...

Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North ...

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved ...

Ted Karkus, CEO and Chairman of the Board of Directors, will be presenting at 11AM ET on October 30 th. One-on-one investor meetings will be held throughout the day. Interested investors can register ...

Title: Identification of CGT1263, a Potent KRAS Inhibitor with Selectivity for Mutant KRAS over HRAS and NRAS Session Date and Time: Poster Session B, Friday, October 24, 2025 – 12:30 p.m. – 4:00 p.m.